Multiple sources tell HBI that Nordic Capital-owned multinational European Dental Group (EDG) will be back on the market in Q1 ’24. HBI also hears Mehilainen could be back in the shop window soon too.
Pan-European French elderly care giant Clariane (formerly Korian) plans to sell over €1bn worth of assets to help shore up its finances and get its debt-to-equity leverage ratio under 3x by 2025. Its Belgian and Dutch nursing homes are top of the list of potential assets to sell. A real estate investor with close connections to the company tells us this will involve the sale of the opco as well as the propco, but a Clariane spokesperson declined to confirm this for us.
It seems Dutch dentistry consolidation could be over before it had really begun, with a consultant source telling HBI the pool of top targets is drying up.
As French nursing home operator Orpea polishes its public image in the Netherlands, HBI catches up with Rune Aresvik, founder of Vardetun consultancy, to hear how the operator is proactively stepping out of the shadows to promote itself, and why its subsidiary Dagelijks Leven is emerging as something of a success story.
Voters in the Netherlands, Belgium, and the UK will take to the ballot box in the next 12 months or so, and make their voices heard. HBI asks what this might mean for the future of the for-profit healthcare sector in those countries.
The longstanding bidding war for pan-European diagnostic firm Alliance Medical Group is over, with iCON Infrastructure confirmed as the new buyer. The £910m deal ends months of speculation. HBI asks a UK-based consultant what this means for the market.
Elderly care in the Netherlands has been stuck in a state of limbo for a while now. Political upheaval over the summer and the collapse of a four-party coalition government after 18 months in power has only made the future of care - and the implementation of planned budget cuts - harder to predict. HBI chats to a consultant to find out more.
HBI hears that the longstanding sale of UK diagnostic firm Alliance Medical Group is imminent, with two bidders left in the process and pan-European operator Affidea tipped to be the front-runner. We speak to three market experts to find out more about the deal which is being valued at around $800m-$1bn.
Orpea Belgium’s 2022 results are public, and it doesn’t look good. Having suffered a historic loss approaching €400 million last year and with Orpea looking to sell its non core business, we ask a market expert whether and when divestment there looks likely.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.OkCookies Policy
